-
"Never forget the person in all the effort we make towards cures" -
@julievraskin such an important reminder to us all!#orphandrugs pic.twitter.com/Tt8q080rCr
-
Since the OMP regulation was installed, nearly 2000 positive opinions for orphan designations have been adopted by COMP and the EC, resulting in 165 authorised OMPs across the EU (March 2019)
#RareDiseases#OrphanDrugs pic.twitter.com/ez66Q7cIRF
-
Delighted to be attending the World Orphan Drug Congress in Barcelona this week! Stop by and say
at stand 38! @orphan_drugs#rarediseases#orphandrugs pic.twitter.com/N1Usowec2Z
-
Full house at
#Semalytix hosting a roundtable at World Orphan Drug Congress. Dr. Yannick Loonus: "How could Artificial Intelligence improve uncovering unmet needs in rare diseases and enhance patient identification"#WODC2019#pharma#ai#rwe#Orphandrugs#RareDiseasepic.twitter.com/l6uzTwIX7U
-
What a great opportunity to be able to take the stage not once, but twice at the 10th
#OrphanDrugs and#RareDiseases West Coast 2019. Honored to present with my good friend,@Harsharajasimha Founder of Organization for Rare Diseases India, USA on "Buildi…https://lnkd.in/gnWD9TX -
#ORPH interims - combination of Venn and@OpenOrphan has given us a strong platform to build full-service, high margin consultancy to offer services to fast-growing#orphandrugs market#raredrugs https://novuscomms.com/2019/09/25/open-orphan-orph-interim-results-for-6-months-ended-30-june-2019/ …pic.twitter.com/rqsGssCxZI
-
On 3 June we will publish our briefings on the
#EU pharmaceutical incentive review#SPC#dataexclusivity#orphandrugs. Do not miss it and sign up for our newsletter: https://medicineslawandpolicy.org/updates/ pic.twitter.com/5CufMOpZ5X
-
Looking for some good news on a Wednesday morning? For the first time EVER,
#orphandrugs comprised a majority of novel drugs approved by@US_FDA in 2018!! Now that’s what I call progress!#RareDiseasePrikaži ovu nit -
Day 2 at the World Orphan Drug Congress in Barcelona. Happy to help raise awareness of http://ataxia-aware.com
#raredisease#orphandrugs#congress#WODC2019#kNOwATAXIA@Ataxia_and_Mepic.twitter.com/5jp1wz662b
-
Happy to announce that our President and CEO, Krishnan Nandabalan, will present at this year’s
#WODCUSA on April 10th, at 3:40 pm. Stop by if you’d like to see how ML and AI can accelerate and de-risk drug development for#RareDiseases.#OrphanDrugs https://bit.ly/2ORHrja pic.twitter.com/0LeWHSzW13
-
@OPENHealth are all set up at the@orphan_drugs World Orphan Drug Congress in Barcelona!
Interesting workshops this morning; including discussion on how to create sustainable access models for gene and other advanced therapies #RareDiseases#OrphanDrugs#wodc2019pic.twitter.com/DplYfWbKMA
-
Neuropore Receives Orphan Drug Designation for NPT520-34 for Treatment of ALS. Read more: https://www.businesswire.com/news/home/20190814005184/en/Neuropore-Receives-Orphan-Drug-Designation-NPT520-34-Treatment …
#NPT#ALS#Parkinsons#OrphanDrugs#Neuroporepic.twitter.com/UnyQBDTx8H
-
Great kickoff of
@eurordis symposium by@yann_eurordis. 1- we are not faced w/ a tsunami of#orphandrugs putting healthcare budgets @ risk 2-there are system failures & misconceptions hampering#access2meds 3- a bold proposal on increased EU cooperation!#RareEU2019pic.twitter.com/huP1otDNCN
-
Excellent talk of Dr Verdes on
#OrphanDrugs, in A Corunna, Spain.#alpha1 antitrypsin augmentation therapy: How is it possible such a high cost for a drug that takes so long on the market? @cdelav @SOGAPAR@pedrojmarcos @Alfa1Espanapic.twitter.com/AUNdzUs2Sd
-
Catalonia: reflective multicriteria decision analysis methodology as a tool to support the decision-making process for https://www.ncbi.nlm.nih.gov/labs/pubmed/31248421-implementing-reflective-multicriteria-decision-analysis-mcda-to-assess-orphan-drugs-value-in-the-catalan-health-service-catsalut/ …
#OrphanDrugs#RareDisease#MalaltiesMinoritàries -
Ready to discuss
#RareDiseases#paediatric and#orphandrugs#incentives today with@EU_Health at Square Brussels!pic.twitter.com/Wk0gIgYcv7
-
Kicking off
#WODCUSA with an intro by Dolon on the risky & costly business model of developing#orphandrugs. How so? Check the graph assessing of the economic viability. Reds = costs; greens = potential revenues...that then need to adjust for risks.@EUCOPEpic.twitter.com/GfARNZI4sU
-
#ORPH@OpenOrphan issues formal compulsory acquisition notices to@hVIVO_UK shareholders who have not yet accepted the Offer (2.47 Open Orphan shares for every one hVIVO share)#orphandrugs#RareDisease https://novuscomms.com/2020/01/28/open-orphan-orph-compulsory-acquisition-of-remaining-hvivo-shares/ …pic.twitter.com/mzZ3ZbsPki
-
Currently discussing rare diseases with David Snow, CBO at
$ELOX at#biotechshowcase#jpm19#orphandrugs#cysticfibrosispic.twitter.com/lk6mnBRUlq
-
From
#BIO2019 in Philadelphia, Minoryx announces first patient dosed in Phase II clinical trial in Friedreich's#Ataxia@HospitalULaPaz http://ow.ly/v8Xp30oTunG#OrphanDrugs#RareDiseasespic.twitter.com/PSYRh451zG
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.